Pages that link to "Q37844721"

The following pages link to Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. (Q37844721):

Displaying 41 items.

• Psoriasis: classical and emerging comorbidities (Q28088340) (← links)
• Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI (Q28476636) (← links)
• The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence. (Q30383929) (← links)
• Resource Use and Costs Associated with Coeliac Disease before and after Diagnosis in 3,646 Cases: Results of a UK Primary Care Database Analysis (Q31074752) (← links)
• Economic impact of biologic utilization patterns in patients with psoriatic arthritis (Q33840422) (← links)
• Tumor necrosis factor inhibitors - state of knowledge (Q34974335) (← links)
• Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care. (Q35180222) (← links)
• Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques (Q36080973) (← links)
• Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries? (Q36404862) (← links)
• Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis (Q36479450) (← links)
• Administration costs of intravenous biologic drugs for rheumatoid arthritis (Q37301258) (← links)
• Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. (Q37453027) (← links)
• Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies. (Q37515034) (← links)
• Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. (Q37520856) (← links)
• Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale (Q37709832) (← links)
• Altered bone biology in psoriatic arthritis (Q38010645) (← links)
• Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. (Q38104769) (← links)
• Use of implicit and explicit bayesian methods in health technology assessment. (Q38122249) (← links)
• Diagnosing and treating psoriatic arthritis: an update (Q38165235) (← links)
• Psoriatic arthritis: recent progress in pathophysiology and drug development. (Q38194559) (← links)
• Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials (Q38211315) (← links)
• Ultrasound in psoriatic arthritis. Can it facilitate a best routine practice in the diagnosis and management of psoriatic arthritis? (Q38571849) (← links)
• How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis (Q38687870) (← links)
• Treatment of psoriasis with etanercept: the typical patient profile (Q38807058) (← links)
• The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence (Q38858194) (← links)
• New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease (Q39373505) (← links)
• The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis (Q40676691) (← links)
• Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults (Q47093829) (← links)
• Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes (Q47259944) (← links)
• Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment (Q47779251) (← links)
• Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study (Q48004654) (← links)
• Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective (Q48379687) (← links)
• Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective (Q49850238) (← links)
• Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK. (Q55452701) (← links)
• The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis. (Q55631301) (← links)
• Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective (Q59337044) (← links)
• A failed attempt at developing a search filter for systematic review methodology articles in Ovid Embase (Q64094769) (← links)
• Errors noted in: Re: Migliore A, Bizzi E, Broccoli S Laganà (2011). Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Published on line June 21st 2011 (Q84972962) (← links)
• Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK (Q90288921) (← links)
• Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective (Q92137651) (← links)
• Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible (Q92628114) (← links)